LEUNASE® contains L-Asparaginase obtained from E. coli HAP modified strain. It has a superior effect in inducing remission, especially for acute lymphoblastic leukemia, and no cross resistance with other drugs.
This page features main products from Kyowa Kirin worldwide portfolio and may not be available in all countries or regions, or may be approved for different indications, in different dosages, or in different strengths. In general, those products are available only by prescription through local healthcare professionals.
Please visit our local country or region website for local information: